Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral
Anna Maria Sironi1, Alessandro Pingitore, Sergio Ghione
1Metabolism and MRI Laboratory, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Via Moruzzi, 1-S Cataldo, 56124 Pisa, Italy. sironi@ifc.cnr.it
Insights
Early hypertension reduces regional heart function, even with normal global cardiac performance. Insulin resistance, visceral fat, and dyslipidemia are linked to this decline.
Area of Science:
- Cardiology
- Metabolic Syndrome
- Medical Imaging
Background:
- Mild-to-moderate hypertension is frequently linked to insulin resistance and visceral adiposity.
- The independent impact of these metabolic abnormalities on regional cardiac function remains unclear.
Purpose of the Study:
- To investigate the effects of elevated blood pressure, insulin resistance, and ectopic fat on peak systolic circumferential strain.
- To assess the relationship between these factors and regional cardiac function in men.
Main Methods:
- Cardiac magnetic resonance (MR) imaging with tissue tagging was used to evaluate regional function.
- MR imaging quantified abdominal visceral and epicardial fat.
- Oral glucose tolerance tests assessed glucose tolerance and insulin resistance; serum lipid profiles were analyzed.
Main Results:
- Circumferential shortening progressively decreased across blood pressure groups (normal, prehypertension, hypertension).
- Reduced circumferential strain correlated with higher blood pressure, independent of age.
- Strain reduction was also associated with epicardial/visceral fat, triglycerides, and insulin resistance, independent of age and blood pressure.
Conclusions:
- Regional left ventricular function is impaired in early hypertension stages, despite normal global function.
- Insulin resistance, dyslipidemia, and ectopic fat accumulation are associated with reduced regional systolic function.
Abstract:
Mild-to-moderate hypertension is often associated with insulin resistance and visceral adiposity. Whether these metabolic abnormalities have an independent impact on regional cardiac function is not known. The goal of this study was to investigate the effects of increased blood pressure, insulin resistance, and ectopic fat accumulation on the changes in peak systolic circumferential strain. Thirty-five male subjects (age: 47+/-1 years; body mass index: 28.4+/-0.6 kg m(-2); mean+/-SEM) included 13 with normal blood pressure (BP: 113+/-5/67+/-2 mm Hg), 13 with prehypertension (BP: 130+/-1/76+/-2 mm Hg), and 9 newly diagnosed with essential hypertension (BP: 150+/-2/94+/-2 mm Hg) who underwent cardiac magnetic resonance tissue tagging (MRI) and MRI quantitation of abdominal visceral and epicardial fat. Glucose tolerance, on oral glucose tolerance test, and insulin resistance were assessed along with the serum lipid profile. All of the subjects had normal glucose tolerance, left- and right-ventricular volumes, and ejection fraction. Across the BP groups, left ventricular mass tended to increase, and circumferential shortening was progressively reduced at basal, midheart, and apical segments (on average, from -17.0+/-0.5% in normal blood pressure to -15.2+/-0.7% in prehypertension to -13.6+/-0.8% in those newly diagnosed with essential hypertension; P=0.004). Reduced circumferential strain was significantly associated with raised BP independent of age (r=0.41; P=0.01) and with epicardial and visceral fat, serum triglycerides, and insulin resistance independent of age and BP. In conclusion, regional left ventricular function is already reduced at the early stages of hypertension despite the normal global cardiac function. Insulin resistance, dyslipidemia, and ectopic fat accumulation are associated with reduced regional systolic function.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease I: Introduction
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
